Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
=== Blood parameters === During acute inflammatory periods, people with AS may show an increase in the blood concentration of CRP and an increase in the ESR, but there are many with AS whose CRP and ESR rates do not increase, so normal CRP and ESR results do not always correspond with the amount of inflammation that is actually present. In other words, some people with AS have normal levels of CRP and ESR, despite experiencing a significant amount of inflammation in their bodies.
For example, many mutations lower the stability of proteins, while ligand binding usually increases protein stability. Using DSC, this stability can be measured by obtaining Gibbs Free Energy values at any given temperature. This allows researchers to compare the free energy of unfolding between ligand-free protein and protein-ligand complex, or wild type and mutant proteins. DSC can also be used in studying protein/lipid interactions, nucleotides, drug-lipid interactions. In studying protein denaturation using DSC, the thermal melt should be at least to some degree reversible, as the thermodynamics calculations rely on chemical equilibrium.
A 2012 study published in the Skeptical Inquirer examined the grants and awards funded by NCCIH from 2000 to 2011, which totaled $1.3 billion. The study found no discoveries in complementary and alternative medicine that would justify the existence of this center. The authors argued that after 20 years and an expenditure of $2 billion, the failure of NCCIH was evidenced by the lack of publications and the failure to report clinical trials in peer-reviewed medical journals. They recommended that NCCIH be defunded or abolished and the concept of funding alternative medicine be discontinued. In 2019, an analysis by the Center for Inquiry found that NCCIH was continuing to fund questionable science and that "there is little hope of reforming the NCCIH as it is currently incorporated". It concluded that "There is no legitimate function that the NCCIH can serve that could not be better carried out by other existing organizations within the NIH umbrella." Writing for Quackwatch in 2023, William London criticized the NCCIH and its article "6 Things To Know When Selecting a Complementary Health Practitioner" for "misleading consumers" and promoting—rather than warning against—complementary health, which "is often a euphemism for quackery."
The radioactive decay constant, the probability that an atom will decay per year, is the solid foundation of the common measurement of radioactivity. The accuracy and precision of the determination of an age (and a nuclide's half-life) depends on the accuracy and precision of the decay constant measurement. The in-growth method is one way of measuring the decay constant of a system, which involves accumulating daughter nuclides. Unfortunately for nuclides with high decay constants (which are useful for dating very old samples), long periods of time (decades) are required to accumulate enough decay products in a single sample to accurately measure them. A faster method involves using particle counters to determine alpha, beta or gamma activity, and then dividing that by the number of radioactive nuclides. However, it is challenging and expensive to accurately determine the number of radioactive nuclides. Alternatively, decay constants can be determined by comparing isotope data for rocks of known age. This method requires at least one of the isotope systems to be very precisely calibrated, such as the Pb–Pb system.
== Interpretation == One study reviewed the relative diagnostic value of enzyme and bicarbonate concentrations compared with enzyme output in 363 secretin-CCK tests. The investigators also evaluated the requirement for perfusion markers to accurately quantify volume, and the validity of a shortened sampling time (first 20 minutes). Only 60 percent of volume was recovered with the duodenal aspiration tube, suggesting that marker perfusion to correct for distal loss of secretion is important to accurately quantify volume. Using a trypsin output <50 U/kg/h as the reference standard, measurement of enzyme concentration alone misclassified approximately 10 percent of patients. Use of a shortened collection time misclassified approximately 4 percent of patients. The authors concluded that this was an unacceptably high rate of misclassification and that the standard prolonged collection of fluid using a perfusion marker must be performed to accurately measure exocrine function.
Sources: en.wikipedia.org
Bully: Emil Mansoor Height: 5'9 Weight: 245 lb Victim(s): Anthony and Mo Fighter: Nick Gaston Height: 6'4 Weight: 265 lb Money earned by Bully: $0 Money earned by victim(s): $10,000 ($5,000 each) Original airing:
== Technique == The technique for dry needling depends on which tissue is being targeted and the overall objective of the treatment. For example, one of the most common treatment objectives for dry needling, myofascial trigger points (TrPs), differs physiologically from treatments for scar tissue, connective tissue problems, and other medical issues. In the treatment of trigger points for persons with myofascial pain syndrome, dry needling is an invasive procedure in which a filiform needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple, hyperirritable contraction knots related to the production and maintenance of the pain cycle; essentially, myofascial trigger points will generate much local pain upon stimulation or irritation. Deep dry needling for treating trigger points was first introduced by the Czech neurologist Karel Lewit in 1979. Lewit had noticed that the success of injections into trigger points in relieving pain was apparently unconnected to the analgesic used. Dry needling can be divided into categories in terms of depth of penetration: deep and superficial dry needling. Deep dry needling will inactivate myofascial trigger points by provoking a local twitch response (LTR), which is an involuntary spinal cord reflex in which the muscle fibers in the taut band of muscle contract. The LTR indicates the proper placement of the needle in a trigger point. Dry needling that elicits LTRs improves treatment outcomes, and may work by activating endogenous opioids.
For example, the pattern may be 10 press ups, then two minutes rest, 10 press ups, then two minutes rest etc. The ability to recover during an exercise (active recovery), during a training session, and resting between training sessions are all of fundamental importance in strength training. If recovery cannot take place then fatigue may occur leading to worse performance and an increased chance of injury.
== Early life and career == Born in Afagnan in Lacs Prefecture at the Hospital of the Brothers of the Order of Saint-Jean-de-Dieu d'Afagnan, Faure Essozimna Gnassingbé is of Kabye descent and is one of Gnassingbé Eyadéma's many children; his mother is Séna Sabine Mensah. Gnassingbé received his secondary education in Lomé before studying in Paris at the Université Paris-Dauphine, where he received a degree in financial business management; he subsequently obtained a Master of Business Administration degree from George Washington University in the United States. He was elected to the National Assembly of Togo in the October 2002 parliamentary election as a Deputy for Blitta, and in the National Assembly he was coordinator of the commission in charge of privatization. On 29 July 2003, he was appointed as Minister of Equipment, Mines, Posts, and Telecommunications, serving in that position until becoming president in February 2005. Some in the opposition claimed that the amendment of the Constitution in December 2002, lowering the minimum age for the president from 45 years to 35 years, was intended to benefit Gnassingbé. His appointment to the government in July 2003 came after he had already been appearing with his father at official functions and contributed to speculation that he was intended as his father's successor.
Glycoproteins and phosphoproteins are usually associated with covalent bonds since they have a carbohydrate or phosphate residue attached to the side chains of certain amino acid residues like asparagine, serine, and threonine. On the other hand, metalloproteins usually involve coordination bonds where there would be bonds between the metal ions and side chains of some amino acids like histidine, cysteine, or aspartic acid. All of these interactions create stable structures that are important for protein function. It is common for the prosthetic group to contribute to the function of the protein. An example of this is if the prosthetic group is broken away from the protein, the function of that protein is lost. This is seen in hemoglobin. When the heme group of hemoglobin is removed, the function of the protein is lost, making it a nonfunctional protein. This all highlights the prosthetic groups importance in maintaining both the structure and protein activity of conjugated proteins.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.